Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
A mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2). FDA-approved in September 2025 (as FORZINITY) for Barth syndrome — the first approved mitochondria-targeted therapy. Investigational for other indications with mixed trial results.
2 of 12 vendors lab-verified
Verified purity per dollar — the cheapest that's actually been tested
vial · 50mg· ionpeptide.com· price updated today
$139.00✓ $2.78/mg
6% more per mg vs cheapest
single-vial price — packs may be lower
vial · 50mg· peptideplugs.com· price updated today
$130.00✓ $2.60/mg
single-vial price — packs may be lower
vial · 50mg· peptidesupplyco.com· price updated today
Lot SS5006032026· tested 2026-06-08
$130.00✓ $2.60/mg
single-vial price — packs may be lower
vial · 30mg· orosresearch.com· price updated today
$109.99✓ $3.67/mg
29% more per mg vs cheapest
single-vial price — packs may be lower
vial · 50mg· optimasupply.is· price updated today
$200.00−13%
$175.00✓ $3.50/mg
26% more per mg vs cheapest
single-vial price — packs may be lower
vial · 50mg· hydroresearchpeptides.com· price updated today
$200.00−13%
$175.00✓ $3.50/mg
26% more per mg vs cheapest
single-vial price — packs may be lower
vial · 10mg· glacieraminos.shop· price updated today
$49.99✓ $5.00/mg
48% more per mg vs cheapest
single-vial price — packs may be lower
vial · 50mg· realpeptides.co· price updated today
$270.00✓ $5.40/mg
52% more per mg vs cheapest
single-vial price — packs may be lower
vial · 10mg· texpeptide.com· price updated today
$55.00✓ $5.50/mg
53% more per mg vs cheapest
single-vial price — packs may be lower
vial · 10mg· ascensionpeptides.com· price updated today
$79.99−25%
$60.00✓ $6.00/mg
57% more per mg vs cheapest
single-vial price — packs may be lower
vial · 10mg· orbitrexpeptide.is· price updated today
$79.99✓ $8.00/mg
67% more per mg vs cheapest
single-vial price — packs may be lower
vial · 10mg· alpha-peptides.com· price updated today
$35.79$3.58/mg
single-vial price — packs may be lower
20 vendors not shown — trust grade below C, or not enough verified COA data yet. We only list sources with a C grade or better.
Best price trend
Lowest $/mg for SS-31 · verified listings only
$2.60/mg
▼ 26% over 90d
Peptide Plugs has the lowest single-vial SS-31 price at $2.60/mg among 30 COA-verified vendors on Disclosed Labs. Bulk or multi-vial deals may be lower. That's 57% less per mg than the most expensive option.
What is the price range for SS-31?
Research-grade SS-31 ranges from $2.60/mg to $6.00/mg across 12 verified sources, a 57% spread per mg.
How are SS-31 prices verified on Disclosed Labs?
Every listed vendor holds a Grade C or better trust score, computed independently from lab Certificates of Analysis — not from payments or sponsorships. Prices are scraped and fact-checked daily. Vendors cannot pay to improve their ranking.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Use the Full safety panel filter to require endotoxin, sterility, and heavy-metals testing on the current batch — not just HPLC purity.
The original SS-peptide class was described by Zhao, Szeto and colleagues (J Biol Chem 2004, PMID 15178689), showing ~1000-fold concentration at the inner mitochondrial membrane and protection against oxidative cell death. Szeto's 2014 review (Br J Pharmacol, PMID 24117165) reframed the mechanism as cardiolipin-binding rather than antioxidant scavenging. The TAZPOWER trial (NCT03098797) in Barth syndrome, with its 168-week open-label extension (Thompson et al., Genet Med 2024, PMID 38602181), supported FDA accelerated approval of FORZINITY in September 2025 at 40 mg SubQ daily. The Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy (Karaa et al., Neurology 2023, PMID 37268435) FAILED co-primary endpoints of 6-minute walk test and fatigue score, though a post-hoc nuclear-DNA subgroup showed improvement. Phase 2 ReCLAIM-2 in geographic atrophy missed primary endpoints but reduced ellipsoid-zone attenuation; a Phase 3 trial is ongoing. Earlier heart failure trials (PROGRESS-HF) showed only modest signals.
This platform provides informational tools only, not medical advice.
Zhao K et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury (original SS-peptide report, J Biol Chem)
2004
Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics (Br J Pharmacol review)
2014
Karaa A et al. Efficacy and Safety of Elamipretide in Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial (Neurology)
Prices verified as of July 2026. Actual prices may vary. For research use only.
Single-vial list prices by default for a fair head-to-head — switch to Multi-vial / bulk for pack pricing. Estimates only; verify at vendor before purchase. For research use only. Not medical advice.
2023
Disclosed Labs